Alpha Glucosidase Inhibitors Market Report 2026

Alpha Glucosidase Inhibitors Market Overview

• Alpha Glucosidase Inhibitors market size has reached to $4.84 billion in 2025 • Expected to grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Rise In Diabetes Prevalence Fuels Growth Of The Alpha-Glucosidase Inhibitors Market • Market Trend: Pioneering Alpha-Glucosidase Inhibitor For Advanced Type 2 Diabetes Management • North America was the largest region in 2025 and Middle-East is the fastest growing region.

What Is Covered Under Alpha Glucosidase Inhibitors Market?

Alpha-glucosidase inhibitors refer to a class of diabetes drugs that inhibit the intestine's ability to absorb carbohydrates to prevent the development of type 2 diabetes mellitus in people with reduced glucose tolerance. They benefit individuals at risk for hypoglycemia or lactic acidosis. The main types of alpha glucosidase are dumping syndrome and type 2 diabetes. Dumping syndrome refers to a variety of symptoms with rapid gastric emptying after a meal, where food passes from the stomach to the individual duodenum too rapidly which increases the concentration of sugar levels, in which alpha-glucosidase inhibitors are used to slow down food digestion in the gut, reducing peak blood glucose concentrations after meals. The various types of drug classes are acarbose, miglitol, and voglibose, which constituents of glucoamylase, isomaltase, maltase, and sucrase that are distributed via online pharmacies, retail pharmacies, and hospital pharmacies.

What Is The Alpha Glucosidase Inhibitors Market Growth Forecast?

The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to technological advancements in drug formulation, rising adoption of combination therapies, increased investment in digital health monitoring, expansion of online pharmacy channels, development of precision medicine solutions. Major trends in the forecast period include personalized diabetes management solutions, development of low-glycemic diet integrated therapies, increased focus on hypoglycemia-safe medications, growth of combination therapy approaches, expansion of patient-centric digital health platforms.

What Is The Driver Of The Alpha Glucosidase Inhibitors Market?

Rising diabetes prevalence globally is expected to propel the growth of the alpha-glucosidase inhibitors market going forward. Diabetes is a long-term metabolic condition marked by high blood glucose (also known as blood sugar) levels, which can seriously harm the heart, blood vessels, eyes, kidneys, and nerves over time. Alpha-glucosidase inhibitors prevent carbohydrate absorption from the small intestine, which inhibits the rise in postprandial blood glucose concentrations and helps control diabetes. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, rising diabetes prevalence globally is driving the growth of the alpha-glucosidase inhibitors market.

Key Players In The Global Alpha Glucosidase Inhibitors Market

Major companies operating in the alpha glucosidase inhibitors market are Bayer AG, Merck & Co., Alkem Laboratories Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH, AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Hanmi Pharmaceuticals Co. Ltd., Eisai Co. Ltd., Biocon Limited, Cadila Pharmaceuticals Ltd

Global Alpha Glucosidase Inhibitors Market Trends and Insights

Major companies operating in the type 2 diabetes market are focusing on developing innovative therapies to improve glycemic control and patient outcomes. SGLT2 inhibitors work by promoting glucose excretion through urine, helping reduce blood sugar levels in patients with type 2 diabetes. For instance, in January 2023, TheracosBio, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin) to treat adults with type 2 diabetes. Brenzavvy is a unique oral inhibitor of sodium-glucose cotransporter 2 (SGLT2). It is suggested as a supplement to diet and exercise to help people with type 2 diabetes better regulate their blood sugar levels by inducing the kidneys to excrete sugar through urine.

What Are Latest Mergers And Acquisitions In The Alpha Glucosidase Inhibitors Market?

In April 2023, Sanofi S.A., a France-based pharmaceutical company acquired Provention Bio Inc. for an undisclosed amount. With this acquisition, Sanofi aims to expand its diabetes drug portfolio with TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes. Provention Bio Inc. is a US-based company that develops diabetes drugs.

What Defines the Alpha Glucosidase Inhibitors Market?

The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alpha Glucosidase Inhibitors Market Report 2026?

The alpha glucosidase inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alpha glucosidase inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.